肥厚型心肌病中的心房颤动与抗凝治疗
Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.
作者信息
Camm C Fielder, Camm A John
机构信息
University of Oxford, Oxford.
St George's, University of London.
出版信息
Arrhythm Electrophysiol Rev. 2017 Jun;6(2):63-68. doi: 10.15420/aer.2017.4.2.
Abstract
Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications Including stroke and sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated with AF in this population, including the evidence in support of higher stroke risk in patients with HCM with AF compared with the general AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.
摘要
肥厚型心肌病（HCM）是一种常见的遗传性心脏疾病，具有包括中风和心源性猝死在内的众所周知的并发症。HCM与房颤的发生之间存在公认的关联。本综述描述了HCM人群中房颤的流行病学，并分析了房颤发生的危险因素。它进一步讨论了该人群中与房颤相关的结局，包括支持HCM合并房颤患者比一般房颤人群有更高中风风险的证据。最后，阐述了该患者群体抗凝治疗的证据和建议。
相似文献
1
Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.肥厚型心肌病中的心房颤动与抗凝治疗
Arrhythm Electrophysiol Rev. 2017 Jun;6(2):63-68. doi: 10.15420/aer.2017.4.2.
2
Atrial Fibrillation in Hypertrophic Cardiomyopathy.肥厚型心肌病中的心房颤动
JACC Adv. 2024 Aug 20;3(9):101210. doi: 10.1016/j.jacadv.2024.101210. eCollection 2024 Sep.
3
Clinical significance of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者新发心房颤动的临床意义。
ESC Heart Fail. 2021 Dec;8(6):5022-5030. doi: 10.1002/ehf2.13563. Epub 2021 Sep 2.
4
Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.肥厚型心肌病伴心房颤动的当代管理进展
Circulation. 2023 Nov 28;148(22):1797-1811. doi: 10.1161/CIRCULATIONAHA.123.065037. Epub 2023 Nov 27.
5
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.肥厚型心肌病中心房颤动的临床特征和后果。
Circulation. 2017 Dec 19;136(25):2420-2436. doi: 10.1161/CIRCULATIONAHA.117.029267. Epub 2017 Sep 15.
6
Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy - A nationwide cohort study.肥厚型心肌病患者的心房颤动与心脏性猝死风险——一项全国性队列研究
EClinicalMedicine. 2021 Mar 17;34:100802. doi: 10.1016/j.eclinm.2021.100802. eCollection 2021 Apr.
7
Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based study.肥厚型心肌病亚洲患者心房颤动和卒中的患病率和发病率的时间趋势：一项全国基于人群的研究。
Int J Cardiol. 2018 Dec 15;273:130-135. doi: 10.1016/j.ijcard.2018.08.038. Epub 2018 Aug 11.
8
Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?心房颤动与肥厚型心肌病：该对谁进行抗凝治疗？
Clin Res Cardiol. 2015 Oct;104(10):799-802. doi: 10.1007/s00392-015-0876-6. Epub 2015 Jul 2.
9
Percutaneous left atrial appendage closure in patients with hypertrophic cardiomyopathy and persistent atrial fibrillation: 3-year-followed case series.经皮左心耳封堵术治疗肥厚型心肌病合并持续性心房颤动患者：3 年随访病例系列研究。
Medicine (Baltimore). 2023 Apr 25;102(17):e33646. doi: 10.1097/MD.0000000000033646.
10
Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy.阵发性心房颤动的重要性及肥厚型心肌病患者预防栓塞性卒中的性别差异
Circ Rep. 2021 Apr 6;3(5):273-278. doi: 10.1253/circrep.CR-20-0101.
引用本文的文献
1
Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy/Myocarditis Registry of the EURObservational Research Programme of the European Society of Cardiology.肥厚型心肌病与心房颤动：欧洲心脏病学会欧洲观察性研究项目的心肌病/心肌炎注册研究
Open Heart. 2025 Feb 17;12(1):e002876. doi: 10.1136/openhrt-2024-002876.
2
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
3
Incidence, Risk Factors, and Outcomes of Left Atrial Enlargement in Patients Requiring Right Ventricular Pacing: A Retrospective Study of 461 Cases from 2012 to 2020.2012 年至 2020 年 461 例右心室起搏患者左心房扩大的发生率、危险因素和转归：一项回顾性研究。
Med Sci Monit. 2024 May 22;30:e944114. doi: 10.12659/MSM.944114.
4
Prognostic effect of atrial fibrillation on survival in patients with hypertrophic cardiomyopathy: a meta-analysis.心房颤动对肥厚型心肌病患者生存预后的影响：一项荟萃分析。
J Cardiothorac Surg. 2023 Jun 20;18(1):196. doi: 10.1186/s13019-023-02299-x.
5
Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy.间隔心肌切除术治疗梗阻性肥厚型心肌病术后应用胺碘酮预防心房颤动。
ESC Heart Fail. 2021 Dec;8(6):4791-4799. doi: 10.1002/ehf2.13662. Epub 2021 Oct 27.
6
Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.心肌病的抗凝治疗：揭示潜在威胁并个体化应对威胁。
ESC Heart Fail. 2021 Dec;8(6):4737-4750. doi: 10.1002/ehf2.13597. Epub 2021 Sep 8.
7
Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.用于识别肥厚型心肌病患者心房颤动病例及其预测因素的机器学习方法：HCM-AF风险模型
CJC Open. 2021 Feb 2;3(6):801-813. doi: 10.1016/j.cjco.2021.01.016. eCollection 2021 Jun.
8
Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy.阵发性心房颤动的重要性及肥厚型心肌病患者预防栓塞性卒中的性别差异
Circ Rep. 2021 Apr 6;3(5):273-278. doi: 10.1253/circrep.CR-20-0101.
9
Thromboembolism in Patients with Hypertrophic Cardiomyopathy.肥厚型心肌病患者的血栓栓塞症。
Int J Med Sci. 2021 Jan 1;18(3):727-735. doi: 10.7150/ijms.50167. eCollection 2021.
10
Follow-up and prognosis of HCM.肥厚型心肌病的随访与预后
Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):33. doi: 10.21542/gcsp.2018.33.
本文引用的文献
1
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.达比加群酯与华法林在伴有左心室肥厚的房颤患者中的比较——随机长期抗凝治疗评估（RE-LY）研究。
Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
2
Predictors of atrial fibrillation in hypertrophic cardiomyopathy.肥厚型心肌病中心房颤动的预测因素
Heart. 2017 May;103(9):672-678. doi: 10.1136/heartjnl-2016-309672. Epub 2016 Oct 28.
3
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
4
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
5
Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation.
J Am Coll Cardiol. 2016 Jun 28;67(25):3020-1. doi: 10.1016/j.jacc.2016.04.026.
6
7
High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.肥厚型心肌病及心律管理装置患者中，新发及亚临床房颤的高发生率
J Cardiovasc Electrophysiol. 2016 Jul;27(7):779-84. doi: 10.1111/jce.12982. Epub 2016 May 3.
8
Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation.肥厚型心肌病中的卒中和栓塞事件：非房颤患者的风险分层
Stroke. 2016 Apr;47(4):936-42. doi: 10.1161/STROKEAHA.115.012130. Epub 2016 Mar 3.
9
Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .肥厚型心肌病患者的诊断与治疗指南（2012年日本循环学会版）——摘要版
Circ J. 2016;80(3):753-74. doi: 10.1253/circj.CJ-66-0122. Epub 2016 Feb 3.
10
Right Ventricular and Right Atrial Involvement Can Predict Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy?肥厚型心肌病患者右心室和右心房受累能否预测心房颤动？
Int J Med Sci. 2016 Jan 1;13(1):1-7. doi: 10.7150/ijms.13530. eCollection 2016.
Zotero 插件